#USA #Denver #QuantiPath #GenoPATHx #Roger Schaller

QuantiPath Welcomes Roger Schaller to Its Board of Directors

QuantiPath, a pioneering company in the field of rapid pathogen detection and food safety diagnostics, has made a significant announcement regarding its leadership. The company has appointed industry veteran Roger Schaller to its Board of Directors, bringing along over three decades of invaluable experience in molecular diagnostics, next-generation sequencing, and strategic business development.

Expertise and Achievements

Roger Schaller's career is marked by his impactful roles in leading organizations that have shaped the landscape of molecular diagnostics. His history includes key positions at several high-profile companies, such as Cepheid, Life Technologies, and Bio-Rad—all renowned names in global diagnostics and life sciences. At Cepheid, where he served as Director of Sales and later as Senior Director of Business Development, Schaller played a crucial role in driving the global adoption of rapid PCR-based infectious disease detection technologies before the company was acquired by Danaher.

Furthermore, Schaller's tenure at Affymetrix, which was purchased by Life Technologies, and RainDance Technologies, acquired by Bio-Rad, showcases his ability to navigate the complexities of the biotech industry. His leadership roles have extended to multiple startups where he held positions such as Chief Operating Officer (COO) and Chief Commercial Officer (CCO), consistently guiding these companies toward industry-defining success. Most recently, he served as Vice President of Business Development at seqWell, where he spearheaded strategic partnerships with leading genomics and sequencing institutions worldwide.

QuantiPath's Vision for Food Safety

According to John LoPorto, CEO of QuantiPath, Schaller's extensive background and established relationships in the diagnostics, biotech, and food safety industries will be instrumental as the company advances its GenoPATHX platform. LoPorto noted, "Roger has been part of some of the most successful stories in molecular diagnostics and life science discoveries. We are proud to have him bring that experience and perspective to QuantiPath."

The appointment comes at a crucial time as QuantiPath continues its mission of delivering faster and more accurate testing solutions to the food safety industry. With Schaller on board, the leadership team aims to grow the company's presence in the market, starting with the introduction of their novel multiplex Salmonella assay—a significant advancement in food safety diagnostics.

A Commitment to Global Food Safety

Schaller expressed excitement about joining QuantiPath, emphasizing the importance of food safety as a global priority. He remarked, "I'm eager to work with John LoPorto and the QuantiPath team as they launch a new generation of multiplex qPCR testing to market. I look forward to applying my experience to help scale the business and build essential partnerships to enhance our food supply chain."

QuantiPath is dedicated to revolutionizing food safety through precision genetic diagnostics. Its flagship product, GenoPATHX, stands out as a rapid test kit that identifies and quantifies multiple Salmonella serovars simultaneously. This innovative approach provides the food industry with unmatched visibility into microbial contamination, contributing to safer food production.

Conclusion

With Roger Schaller's appointment, QuantiPath reinforces its commitment to leading the charge in food safety testing and diagnostics. Schaller’s expertise and visionary leadership will undoubtedly play a critical role in shaping the future of QuantiPath as it endeavors to meet the growing demands and challenges of food safety in today's complex global environment.